These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 21243457)

  • 21. Doliroside A attenuates monosodium urate crystals-induced inflammation by targeting NLRP3 inflammasome.
    Wei H; Hu C; Xie J; Yang C; Zhao Y; Guo Y; Mei Z; Chen L; Lan Z
    Eur J Pharmacol; 2014 Oct; 740():321-8. PubMed ID: 25064339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha-1-anti-trypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1β and by the induction of endogenous IL-1Ra.
    Joosten LA; Crişan TO; Azam T; Cleophas MC; Koenders MI; van de Veerdonk FL; Netea MG; Kim S; Dinarello CA
    Ann Rheum Dis; 2016 Jun; 75(6):1219-27. PubMed ID: 26174021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Panniculitis: another clinical expression of gout.
    Ochoa CD; Valderrama V; Mejia J; Rondon F; Villaroya N; Restrepo JF; Espinoza LR; Iglesias-Gamarra A
    Rheumatol Int; 2011 Jun; 31(6):831-5. PubMed ID: 20730459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis.
    Cronstein BN; Sunkureddi P
    J Clin Rheumatol; 2013 Jan; 19(1):19-29. PubMed ID: 23319019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing problem gout.
    Fam AG
    Ann Acad Med Singap; 1998 Jan; 27(1):93-9. PubMed ID: 9588282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis.
    Getting SJ; Christian HC; Flower RJ; Perretti M
    Arthritis Rheum; 2002 Oct; 46(10):2765-75. PubMed ID: 12384937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gouty Arthritis: A Review of Acute Management and Prevention.
    Wilson L; Saseen JJ
    Pharmacotherapy; 2016 Aug; 36(8):906-22. PubMed ID: 27318031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gout: the last 50 years.
    Scott JT
    J R Soc Med; 1996 Nov; 89(11):634-7. PubMed ID: 9135593
    [No Abstract]   [Full Text] [Related]  

  • 29. Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review.
    Curiel RV; Guzman NJ
    Semin Arthritis Rheum; 2012 Oct; 42(2):166-78. PubMed ID: 22560299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapy of hyperuricemia and gout].
    Pöllmann G; Kullich W; Klein G
    Wien Med Wochenschr; 1997; 147(16):382-7. PubMed ID: 9446417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disseminated Cutaneous Tophi in a Patient with Chronic Tophaceous Gout and Renal Impairment: A Case Report of a Rare Manifestation of Gout.
    Parlindungan F; Setiyohadi B; Arisanti R
    Am J Case Rep; 2020 Apr; 21():e919349. PubMed ID: 32241962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of gouty arthritis in patients with chronic kidney disease.
    Abdellatif AA; Elkhalili N
    Am J Ther; 2014; 21(6):523-34. PubMed ID: 22960848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gouty arthritis: understanding the disease state and management options in primary care.
    Sunkureddi P
    Adv Ther; 2011 Sep; 28(9):748-60. PubMed ID: 21894471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The current state of care in gout: Addressing the need for better understanding of an ancient disease.
    Zychowicz ME; Pope RS; Graser E
    J Am Acad Nurse Pract; 2010 Nov; 22 Suppl 1():623-36. PubMed ID: 21054636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spondyloarthritis as a presentation of gouty arthritis.
    Justiniano M; Colmegna I; Cuchacovich R; Espinoza LR
    J Rheumatol; 2007 May; 34(5):1157-8. PubMed ID: 17477478
    [No Abstract]   [Full Text] [Related]  

  • 36. Should patients with interval gout be treated with urate lowering drugs?
    Fam AG
    J Rheumatol; 1995 Sep; 22(9):1621-3. PubMed ID: 8523333
    [No Abstract]   [Full Text] [Related]  

  • 37. Acute gout of the right sacroiliac joint.
    Abraham Z; Glück Z
    J Dermatol; 1997 Dec; 24(12):781-3. PubMed ID: 9492443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Control of flares and relief of urate burden with canakinumab and targeted urate-lowering therapy in tophaceous gouty arthritis.
    Fanouriakis A; Karantanas A; Fragouli E; Repa A; Sidiropoulos P
    Rheumatology (Oxford); 2014 Apr; 53(4):764-6. PubMed ID: 24185764
    [No Abstract]   [Full Text] [Related]  

  • 39. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.
    Khanna D; Khanna PP; Fitzgerald JD; Singh MK; Bae S; Neogi T; Pillinger MH; Merill J; Lee S; Prakash S; Kaldas M; Gogia M; Perez-Ruiz F; Taylor W; Lioté F; Choi H; Singh JA; Dalbeth N; Kaplan S; Niyyar V; Jones D; Yarows SA; Roessler B; Kerr G; King C; Levy G; Furst DE; Edwards NL; Mandell B; Schumacher HR; Robbins M; Wenger N; Terkeltaub R;
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1447-61. PubMed ID: 23024029
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-gout and Urate-lowering Potentials of Curcumin: A Review from Bench to Beside.
    Jafari-Nozad AM; Jafari A; Yousefi S; Bakhshi H; Farkhondeh T; Samarghandian S
    Curr Med Chem; 2024; 31(24):3715-3732. PubMed ID: 37488765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.